CG Oncology price target raised to $82 from $55 at Goldman Sachs

Goldman Sachs raised the firm’s price target on CG Oncology (CGON) to $82 from $55 and keeps a Buy rating on the shares. CG Oncology’s advancement of the pivotal PIVOT-006 readout for cretostimogene to the second half of 2026, nearly a year ahead of schedule, positions the program for a potential first-mover advantage in a large Intermediate-Risk Non-Muscle-Invasive Bladder Cancer market with no broadly approved adjuvant therapies, the analyst tells investors in a research note. The randomized surveillance-controlled design aligns with guidelines and represents a key 1H26 de-risking catalyst, supporting a $2.5B peak sales opportunity and potential establishment as a first-in-class standard of care, Goldman says.